April 2013 - Page 20 of 21

TuesdayApr 02, 2013 1:32 pm

Dr. Adam J. Simon Joins Amarantus BioScience, Inc. (AMBS) Board of Advisors

Amarantus BioScience announced that Adam J. Simon, Ph.D., has been appointed to its Board of Advisors. Dr. Simon is a world-renowned expert in working with Alzheimer’s disease biomarkers, and also has significant expertise in the development of in-vitro diagnostics; these qualifications make him a welcome addition to the biotechnology, which focuses on discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis. Gerald E. Commissiong, Amarantus’s President and CEO, remarked, "Dr. Simon will play an important role in the development of our LymPro diagnostic blood test for Alzheimer's disease. He is a recognized leader in the discovery…

TuesdayApr 02, 2013 11:26 am

SmallCapVoice: Terra Tech Corp. (TRTC) Taps Former Executive Director of the FDA for Advisory Board

Terra Tech, a leader in sustainable agricultural products, is pleased to announce the appointment of Dr. Ronald Hart to the company’s Advisory Board. Dr. Hart is an internationally recognized scientist, scholar and expert in business acceleration strategies for emerging growth companies. He is the former Chief Scientist and Executive Director of the FDA’s National Center for Toxicology Research and was the first person in the history of the FDA to be named “distinguished scientist in residence.” In addition, he was an author of the Federal Technology Transfer Act of 1986. “Dr. Harts broad and accomplished background is a significant asset…

TuesdayApr 02, 2013 11:24 am

CEL-SCI Corp. (CVM) Releases Video on Cancer Drug Multikine

CEL-SCI is focused on its research and development initiatives directed at improving the treatment of cancer and other diseases by using the body's natural defense system, the immune system. It is developing treatments for use against cancer, rheumatoid arthritis, and various viruses, including H1N1, H5N1, and the Avian Flu. Its lead investigational drug is Multikine (Leukocyte Interleukin, Injection), which is currently being studied in a key global Phase III clinical trial. Multikine is the first immunotherapeutic agent being developed as a potential first-line treatment for advanced primary head and neck cancers. It would be the first-of-its-kind treatment, using the immune…

TuesdayApr 02, 2013 11:20 am

New Executive Appointments Announced by The Wet Seal, Inc. (WTSL)

Leading young women’s specialty retailer The Wet Seal announced the promotions of its two divisional merchandising managers for the Wet Seal brand. Kim Bajrech has been newly appointed to the role of senior vice president-general merchandising manager of apparel, and Debbie Shinn has been promoted to senior vice president-general merchandising manager of accessories and ready-to-wear. Each woman has previously served as vice president-divisional merchandising manager of apparel and vice president-divisional merchandising manager of accessories and ready-to-wear, respectively. Their new promotions were effective as of March 25, and both women will continue reporting to CEO John Goodman. “We are thrilled to…

TuesdayApr 02, 2013 10:33 am

Ku6 Media Co., Ltd. (KUTV) Makes Changes to Management Team

Ku6 Media, a leading internet video company in China focusing on user-generated content (UGC), today announced that Mr. Kelvin Wenbo Liu has joined the company as President and Mr. Jian Lu has been appointed as Chief Technology Officer of the company. "We are very excited to have Kelvin and Jian join our management team, leading our efforts around building the Company's video services on the basis of cloud infrastructure," stated Mr. Jeff Shi , Chief Executive Officer of Ku6 Media. "Kelvin and Jian are both accomplished and rigorous business leaders with incredibly expertise in the technologies that are vital to…

TuesdayApr 02, 2013 10:28 am

The Aristocrat Group Corp. (ASCC) Leveraging Cocktail of Marketing Strategies to Promote New Vodka Lines

The Aristocrat Group Corp. today gave a broad overview of its strategy to capitalize on the fast-growing super-premium vodka segment, which has increased 32 percent in the last two years to $1.2 billion. Vodka, which accounts for 32 percent of industry volume, increased 5.9 percent in 2011 and now counts for a third of all spirits consumed in America. ASCC’s brand management division, Luxuria Brands, is constructing a marketing strategy that will position ASCC as a competitive player in the highly lucrative beverage industry, honing a specific focus on vodka branding and marketing. As ASCC executes its plan to introduce…

TuesdayApr 02, 2013 10:26 am

Cord Blood America, Inc. (CBAI) Posts FY2012 Financial Results, Offers Favorable View for 2013

Cord Blood America reported its full-year 2012 financial results for the 12 months ended December 31, 2012, reflecting a revamped business model. Revenues for 2012 clipped a record $6.0 million, up 18 percent from $5.1 million reported in the year-ago period. Gross profit for the year increased by 20 percent to $4.20 million from $3.5 million reported in the comparable period of 2011. Administrative and selling expenses for the year decreased by 17 percent to $5.63 million, compared to $6.75 million for the year prior. Positive cash flow from operations increased 117 percent to $0.19 million vs. the year ago…

TuesdayApr 02, 2013 10:25 am

Cellceutix Corp. (CTIX) Announces Selection of Kevetrin™ Abstract for Poster Presentation at 2013 ASCO Meeting

Cellceutix, a clinical stage biopharmaceutical company driving towards the discovery of small molecule drugs for the treatment of unmet medical conditions, announced that its abstract on Kevetrin™, the company’s flagship cancer drug candidate currently in clinical trials at Dana-Farber Cencer Center and Beth Israel Deaconess, will be a part of the poster presentation at the 2013 American Society of Clinical Oncology (“ASCO”) Annual Meeting. The annual ASCO meeting is from May 31 through June 4, 2013, in Chicago, Illinois. The “General Poster Session: Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics” portion of the symposium will feature Cellceutix’s abstract titled,…

TuesdayApr 02, 2013 9:22 am

Loans4Less.com, Inc. (LFLS) Reports Anticipation of Becoming Fully Reporting by 2014

Loans4Less.com, a publicly traded online mortgage loan brokerage focused on Conforming loans, today announced that it is on target to become a fully reporting company next year. The company’s Annual Report & Audited Financials for 2012 have been posted at www.otcmarkets.com/stock/LFLS/filings. The online mortgage loan brokerage also reported initiatives to ink licensing and/or joint-venture arrangements as well as possibly pursue other loan products to rebrand Loans4Less.com as a general loan consumer portal while continuing to offer mortgages as its base service. Steven M. Hershman, Chairman & President, commented, "We are excited to be on track to become a fully reporting…

TuesdayApr 02, 2013 8:53 am

Rainbow Coral Corp. (RBCC) Launches New Website, Highlights Impressive Deal Flow

Last week, Rainbow BioSciences, the biotechnology division of Rainbow Coral Corp., revealed a new website highlighting its explorations into the multi-billion-dollar drug delivery and genome-mapping market. The new website replaces the prior version and can be found at www.rainbowbiosciences.com. The revamped site details the company’s new partnership with TheraKine Ltd., the developer of a revolutionary, sustained-release drug delivery platform that could soon make local delivery of biologic agents and small molecules safer, more effective, and more convenient than ever before. Some experts believe that the worldwide market for the 10 most popular drug delivery technologies (DDTs) alone could grow to…

Site Search

Company Search

Month: April 2013